BRIEF published on 10/21/2024 at 20:05, 1 year 3 months ago ABIONYX Pharma reçoit un avis favorable de l'EMA pour le CER-001 ABIONYX Pharma CER-001 EMA Déficience LCAT AMM
BRIEF published on 10/21/2024 at 20:05, 1 year 3 months ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 3 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma reçoit un avis positif de l'EMA pour le CER-001 dans la Déficience en LCAT. L'EMA admissible à la soumission de deux lots prospectifs de validation du procédé de fabrication ABIONYX Pharma CER-001 EMA LCAT Validation Du Procédé
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 3 months ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 5 months ago ABIONYX Pharma : Bilan du 1er semestre 2024 Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
BRIEF published on 08/22/2024 at 18:05, 1 year 5 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 5 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma publie sa position de trésorerie du 1er semestre 2024 avec un chiffre d’affaires consolidé de 2,4 M€. Levée de fonds de 3,4 M€ pour renforcer la trésorerie Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 5 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 1 year 7 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
BRIEF published on 07/01/2024 at 09:27, 1 year 7 months ago ABIONYX finalise avec succès une augmentation de capital de 3,4 millions d'euros Augmentation De Capital Actions Et Bons De Souscription Biotechnologies ABIONYX Développement De La Septicémie
Published on 01/31/2026 at 03:15, 1 day 19 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 21 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 1 day 23 hours ago Avidian Gold Corp. Announces Director Resignation
Published on 02/01/2026 at 20:25, 2 hours 17 minutes ago WHO Makes Historic Pivot to County-Level Governance, Validating "Bottom-Up" Climate-Health Model in Tropical Southern China
Published on 01/31/2026 at 15:54, 1 day 6 hours ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 10 hours ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 19 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 2 days ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 18:40, 2 days 4 hours ago ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 17:45, 2 days 4 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 2 days 4 hours ago Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 2 days 14 hours ago Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés
